Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ac225-DOTA-M5A in Advanced or Metastatic Cancers
NCT05204147Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Jun 2022
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 225Ac-DOTA-M5A in colorectal cancer (CRC), sponsored by City of Hope. Primary endpoints: Incidence of adverse events at 6 months and Maximum tolerated dose at 36 months. Started Jun 2022; status: recruiting.
02
Drugs
225Ac-DOTA-M5A
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05204147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05204147.